Your browser doesn't support javascript.
loading
Cell-free RNA Liquid Biopsy to Monitor Hematopoietic Stem Cell Transplantation.
Loy, Conor; Cheng, Matthew P; Gonzalez-Bocco, Isabel H; Lenz, Joan; Belcher, Emma; Bliss, Andrew; Eweis-LaBolle, Daniel; Chu, Tinyi; Ritz, Jerome; De Vlaminck, Iwijn.
Affiliation
  • Loy C; Meinig School of Biomedical Engineering, Cornell University; Ithaca, 14850, USA.
  • Cheng MP; Department of Molecular Biology and Genetics, Cornell University; Ithaca, 14853, USA.
  • Gonzalez-Bocco IH; Department of Medical Oncology, Dana-Farber Cancer Institute; Boston, 02215, USA.
  • Lenz J; Division of Infectious Disease, Brigham and Women's Hospital; Boston, 02215, USA.
  • Belcher E; Department of Medical Oncology, Dana-Farber Cancer Institute; Boston, 02215, USA.
  • Bliss A; Division of Infectious Disease, Brigham and Women's Hospital; Boston, 02215, USA.
  • Eweis-LaBolle D; Meinig School of Biomedical Engineering, Cornell University; Ithaca, 14850, USA.
  • Chu T; Meinig School of Biomedical Engineering, Cornell University; Ithaca, 14850, USA.
  • Ritz J; Meinig School of Biomedical Engineering, Cornell University; Ithaca, 14850, USA.
  • De Vlaminck I; Department of Molecular Biology and Genetics, Cornell University; Ithaca, 14853, USA.
medRxiv ; 2024 May 16.
Article de En | MEDLINE | ID: mdl-38798589
ABSTRACT
Hematopoietic Stem Cell Transplantation (HSCT) is one of the oldest and most successful immunotherapies. Yet, despite long-standing success in the use of HSCT for the treatment of blood cancers and severe immune disorders, monitoring post-transplant complications remains a challenge due to a lack of informative diagnostic tests. Here, we investigate the utility of cell-free RNA (cfRNA) in plasma as a liquid biopsy to monitor allogeneic HSCT recipients during and after treatment. We assayed longitudinal samples from 92 HSCT recipients by cfRNA sequencing and show that cfRNA provides insight into treatment and recovery trajectories, immune dynamics in response to transplantation, infection, and solid-tissue injury associated with Graft-Versus-Host Disease. Collectively, our results provide support for the use of plasma cfRNA profiling to monitor complications of HSCT.

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Langue: En Journal: MedRxiv Année: 2024 Type de document: Article Pays d'affiliation: États-Unis d'Amérique

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Langue: En Journal: MedRxiv Année: 2024 Type de document: Article Pays d'affiliation: États-Unis d'Amérique
...